{"id":90355,"topic":"peptides","source":"reuters.com","title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","url_hash":"89fb159f53487243c560c39e4649b86cb5711cbf","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5\" target=\"_blank\">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">reuters.com</font>","content":null,"image_url":null,"lang":"en","published_at":"2026-07-01T07:00:00+00:00","fetched_at":"2026-09-25T17:15:11+00:00","status":"read","starred":0,"extract_state":"failed","summary_auto":null,"cluster_id":null,"extract_retries":2,"extract_error":"http_401","contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_401).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":493,"usable_text_length":493,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_401","extract_retries":2,"content_length":0,"summary_length":493}},"news_item":{"id":90355,"canonical_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","source_name":"reuters.com","author":null,"published_at":"2026-07-01T07:00:00+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5\" target=\"_blank\">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">reuters.com</font>","full_text":null,"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5\" target=\"_blank\">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">reuters.com</font>","extraction":{"state":"failed","confidence":0.0,"error":"http_401","explanation":"Low confidence: HTTP extraction failure (http_401).","diagnostics_url":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_401).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":493,"usable_text_length":493,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_401","extract_retries":2,"content_length":0,"summary_length":493}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","summary":"<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5\" target=\"_blank\">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">reuters.com</font>","source":"reuters.com","date":"2026-07-01T07:00:00+00:00","content":"","confidence":0.0,"diagnostics_url":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","quality_bucket":"failed","failure_kind":"http","retryable":false,"quality_reason":"Low confidence: HTTP extraction failure (http_401).","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_401).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":493,"usable_text_length":493,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_401","extract_retries":2,"content_length":0,"summary_length":493}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/90355","export_markdown":"/api/items/90355/export?format=markdown","export_json":"/api/items/90355/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/"},"formats":{"full":{"id":90355,"title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","source":"reuters.com","author":null,"published_at":"2026-07-01T07:00:00+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5\" target=\"_blank\">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">reuters.com</font>","full_text":null,"reading_time_min":1,"extraction":{"state":"failed","confidence":0.0,"error":"http_401","explanation":"Low confidence: HTTP extraction failure (http_401).","diagnostics_url":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_401).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":493,"usable_text_length":493,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_401","extract_retries":2,"content_length":0,"summary_length":493}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_401).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":493,"usable_text_length":493,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_401","extract_retries":2,"content_length":0,"summary_length":493}},"actions":{"read":"/item/90355","export_markdown":"/api/items/90355/export?format=markdown","export_json":"/api/items/90355/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/"}},"digest":{"id":90355,"title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","source":"reuters.com","topic":"peptides","published_at":"2026-07-01T07:00:00+00:00","excerpt":"<a…","quality_bucket":"failed","quality_reason":"Low confidence: HTTP extraction failure (http_401).","reading_time_min":1,"cluster_id":null},"card":{"display_title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","subtitle":"reuters.com · 2026-07-01","summary":"<a…","badges":["quality:failed","issue:http"],"links":{"read":"/item/90355","original":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","diagnose":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/"},"quality_warning":"Low confidence: HTTP extraction failure (http_401)."},"export":{"title":"FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","summary":"<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5\" target=\"_blank\">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">reuters.com</font>","source":"reuters.com","date":"2026-07-01T07:00:00+00:00","content":"","confidence":0.0,"diagnostics_url":"/api/diagnose?url=https%3A//www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/","quality_bucket":"failed","failure_kind":"http","retryable":false,"quality_reason":"Low confidence: HTTP extraction failure (http_401).","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_401).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":493,"usable_text_length":493,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_401","extract_retries":2,"content_length":0,"summary_length":493}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}